Atlas One · Host Biology · Scale 07 — System

Renal Cell Carcinoma

Clear cell RCC (~75%) is driven by VHL loss → HIF activation → VEGF angiogenesis; papillary type driven by MET and CDKN2A. Nivolumab+ipilimumab and pembrolizumab+axitinib are first-line for advanced RCC; cabozantinib is active after ICI progression.

Also known as: renal cell carcinoma, RCC, clear cell RCC, ccRCC, papillary RCC, chromophobe RCC, kidney cancer, renal carcinoma, VHL-mutant RCC

Scale 07 — SystemScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
renal-cell-carcinoma

Renal Cell Carcinoma

Clear cell RCC (~75%) is driven by VHL loss → HIF activation → VEGF angiogenesis; papillary type driven by MET and CDKN2A. Nivolumab+ipilimumab and pembrolizumab+axitinib are first-line for advanced RCC; cabozantinib is active after ICI progression.

Entry Metadata

FieldValue
IDrenal-cell-carcinoma
NameRenal Cell Carcinoma
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toVegf connects-toPd 1 connects-toMtor connects-toHif 1Alpha connects-toKidney connects-toVhl Disease connects-toMet connects-toPheochromocytoma Paraganglioma connects-toHlrcc connects-toT Cytotoxic Cell

Sources